Dataset from A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00006924
下载链接
链接失效反馈官方服务：
资源简介：
The overall objective of this study is to assess the efficacy and safety of treatment with
PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation
powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to
very severe COPD.
创建时间：
2026-02-13
